Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition

Current Medicinal Chemistry

Volumn 19, Issue 9, 2012, Pages 1335-1345

  Rahn, K A ^a   Slusher, B S ^a,b   Kaplin, A I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alzheimer's Disease; cognitive impairment; excitotoxicity; Glutamate; Glutamate Carboxypeptidase II (GCPII); ionotropic glutamate receptor; metabotropic glutamate receptor; Multiple Sclerosis; N Acetyl Apartyl Glutamate (NAAG); NAAG peptidase; NAALADase; neurodegeneration; Schizophrenia; stroke

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA 7 NICOTINIC ACID; CYCLOSERINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; METABOTROPIC RECEPTOR; NICOTINIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN REGION; COGNITIVE DEFECT; EXCITOTOXICITY; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STROKE; UPREGULATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; HUMANS; NEUROPROTECTIVE AGENTS; SYNAPTIC TRANSMISSION;

EID: 84858143876     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799462649     Document Type: Review

References (194)

1. Erecinska, M.; Silver, I. A., Metabolism and role of glutamate in mammalian brain. Prog Neurobiol 1990, 35 (4), 245-96. (Pubitemid 20304100)
2. Takasaki, C.; Yamasaki, M.; Uchigashima, M.; Konno, K.; Yanagawa, Y.; Watanabe, M., Cytochemical and cytological properties of perineuronal oligodendrocytes in the mouse cortex. Eur J Neurosci 2010, 32 (8), 1326-36.
3. Kanamori, K.; Ross, B. D.; Kondrat, R. W., Glial uptake of neurotransmitter glutamate from the extracellular fluid studied in vivo by microdialysis and (13)C NMR. J Neurochem 2002, 83 (3), 682-95. (Pubitemid 35231822)
4. Zahr, N. M.; Mayer, D.; Pfefferbaum, A.; Sullivan, E. V., Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy. Cereb Cortex 2008, 18 (10), 2241-50.
5. Hamdan, F. F.; Gauthier, J.; Araki, Y.; Lin, D. T.; Yoshizawa, Y.; Higashi, K.; Park, A. R.; Spiegelman, D.; Dobrzeniecka, S.; Piton, A.; Tomitori, H.; Daoud, H.; Massicotte, C.; Henrion, E.; Diallo, O.; Shekarabi, M.; Marineau, C.; Shevell, M.; Maranda, B.; Mitchell, G.; Nadeau, A.; D'Anjou, G.; Vanasse, M.; Srour, M.; Lafreniere, R. G.; Drapeau, P.; Lacaille, J. C.; Kim, E.; Lee, J. R.; Igarashi, K.; Huganir, R. L.; Rouleau, G. A.; Michaud, J. L., Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 2011, 88 (3), 306-16.
6. Johnston, M. V., Clinical disorders of brain plasticity. Brain Dev 2004, 26 (2), 73-80. (Pubitemid 38229619)
7. Olney, J. W.; Sharpe, L. G., Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science 1969, 166 (903), 386-8.
8. Gras, G.; Porcheray, F.; Samah, B.; Leone, C., The glutamate-glutamine cycle as an inducible, protective face of macrophage activation. J Leukoc Biol 2006, 80 (5), 1067-75. (Pubitemid 44646312)
9. Espinoza-Rojo, M.; Iturralde-Rodriguez, K. I.; Chanez-Cardenas, M. E.; Ruiz-Tachiquin, M. E.; Aguilera, P., Glucose transporters regulation on ischemic brain: possible role as therapeutic target. Cent Nerv Syst Agents Med Chem 2010, 10 (4), 317-25.
10. Liu, X. H.; Xu, H.; Barks, J. D., Tumor necrosis factor-a attenuates N-methyl-D-aspartate-mediated neurotoxicity in neonatal rat hippocampus. Brain Res 1999, 851 (1-2), 94-104. (Pubitemid 30038133)
11. Gottlieb, M.; Matute, C., Expression of ionotropic glutamate receptor subunits in glial cells of the hippocampal CA1 area following transient forebrain ischemia. J Cereb Blood Flow Metab 1997, 17 (3), 290-300. (Pubitemid 27161372)
12. McDonald, J. W.; Althomsons, S. P.; Hyrc, K. L.; Choi, D. W.; Goldberg, M. P., Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998, 4 (3), 291-7. (Pubitemid 28144086)
13. Li, B.; Zhang, S.; Li, M.; Zhang, H.; Hertz, L.; Peng, L., Down-regulation of GluK2 kainate receptor expression by chronic treatment with mood-stabilizing anti-convulsants or lithium in cultured astrocytes and brain, but not in neurons. Neuropharmacology 2009, 57 (4), 375-85.
14. Karadottir, R.; Cavelier, P.; Bergersen, L. H.; Attwell, D., NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005, 438 (7071), 1162-6. (Pubitemid 41831686)
15. Salter, M. G.; Fern, R., NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005, 438 (7071), 1167-71. (Pubitemid 41831687)
16. Lau, A.; Tymianski, M., Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010, 460 (2), 525-42.
17. Dracheva, S.; Byne, W.; Chin, B.; Haroutunian, V., Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia. Brain Res 2008, 1214, 23-34.
18. Simeone, T. A.; Sanchez, R. M.; Rho, J. M., Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol 2004, 19 (5), 343-60; discussion 361.
19. Gravius, A.; Pietraszek, M.; Dekundy, A.; Danysz, W., Metabotropic glutamate receptors as therapeutic targets for cognitive disorders. Curr Top Med Chem 2010, 10 (2), 187-206.
20. Baskys, A.; Bayazitov, I.; Fang, L.; Blaabjerg, M.; Poulsen, F. R.; Zimmer, J., Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis. Neuropharmacology 2005, 49 Suppl 1, 146-56. (Pubitemid 41115901)
21. Cartmell, J.; Schoepp, D. D., Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000, 75 (3), 889-907. (Pubitemid 30660476)
22. Choi, D. W., Ionic dependence of glutamate neurotoxicity. J Neurosci 1987, 7 (2), 369-79. (Pubitemid 17017466)
23. Cheung, N. S.; Beart, P. M.; Pascoe, C. J.; John, C. A.; Bernard, O., Human Bcl-2 protects against AMPA receptor-mediated apoptosis. J Neurochem 2000, 74 (4), 1613-20. (Pubitemid 30163983)
24. Won, S. J.; Kim, D. Y.; Gwag, B. J., Cellular and molecular pathways of ischemic neuronal death. J Biochem Mol Biol 2002, 35 (1), 67-86. (Pubitemid 35216583)
25. Qin, Z. H.; Chen, R. W.; Wang, Y.; Nakai, M.; Chuang, D. M.; Chase, T. N., Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci 1999, 19 (10), 4023-33. (Pubitemid 29222275)
26. Hansson, O.; Petersen, A.; Leist, M.; Nicotera, P.; Castilho, R. F.; Brundin, P., Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A 1999, 96 (15), 8727-32. (Pubitemid 29354859)
27. Schauwecker, P. E., Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain. Exp Neurol 2010, 224 (1), 207-18.
28. Denes, L.; Szilagyi, G.; Gal, A.; Nagy, Z., Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Brain Res Bull 2006, 70 (3), 260-2. (Pubitemid 44067344)
29. Schielke, G. P.; Kupina, N. C.; Boxer, P. A.; Bigge, C. F.; Welty, D. F.; Iadecola, C., The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat. Stroke 1999, 30 (7), 1472-7.
30. Bassani, S.; Valnegri, P.; Beretta, F.; Passafaro, M., The GLUR2 subunit of AMPA receptors: synaptic role. Neuroscience 2009, 158 (1), 55-61.
31. Mohamed, R.; Shivaprasad, H. V.; Jameel, N. M.; Shekar, M. A.; Vishwanath, B. S., Neutralization of Local Toxicity Induced by Vipera Russelli Phospholipase A(2) by Lipophilic Derivative of Ascorbic Acid. Curr Top Med Chem 2011.
32. Szenasi, G.; Vegh, M.; Szabo, G.; Kertesz, S.; Kapus, G.; Albert, M.; Greff, Z.; Ling, I.; Barkoczy, J.; Simig, G.; Spedding, M.; Harsing, L. G., Jr., 2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. Neurochem Int 2008, 52 (1-2), 166-83.
33. Jayakar, S. S.; Dikshit, M., AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs. Int J Neurosci 2004, 114 (6), 695-734. (Pubitemid 38679908)
34. Ouardouz, M.; Coderre, E.; Basak, A.; Chen, A.; Zamponi, G. W.; Hameed, S.; Rehak, R.; Yin, X.; Trapp, B. D.; Stys, P. K., Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol 2009, 65 (2), 151-9.
35. Olney, J. W.; Rhee, V.; Ho, O. L., Kainic acid: a powerful neurotoxic analogue of glutamate. Brain Res 1974, 77 (3), 507-12.
36. Nadler, J. V.; White, W. F.; Vaca, K. W.; Perry, B. W.; Cotman, C. W., Biochemical correlates of transmission mediated by glutamate and aspartate. J Neurochem 1978, 31 (1), 147-55.
37. McDonald, J. W.; Johnston, M. V., Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Brain Res Rev 1990, 15 (1), 41-70. (Pubitemid 20158154)
38. Riederer, P.; Hoyer, S., From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 2006, 113 (11), 1671-7. (Pubitemid 44657662)
39. Pellegrini-Giampietro, D. E.; Gorter, J. A.; Bennett, M. V.; Zukin, R. S., The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders. Trends Neurosci 1997, 20 (10), 464-70. (Pubitemid 27421709)
40. Anzai, T.; Tsuzuki, K.; Yamada, N.; Hayashi, T.; Iwakuma, M.; Inada, K.; Kameyama, K.; Hoka, S.; Saji, M., Overexpression of Ca2+-permeable AMPA receptor promotes delayed cell death of hippocampal CA1 neurons following transient forebrain ischemia. Neurosci Res 2003, 46 (1), 41-51. (Pubitemid 36506608)
41. Haseldonckx, M.; Van Reempts, J.; Van de Ven, M.; Wouters, L.; Borgers, M., Protection with lubeluzole against delayed ischemic brain damage in rats. A quantitative histopathologic study. Stroke 1997, 28 (2), 428-32. (Pubitemid 27097016)
42. Pulsinelli, W. A.; Brierley, J. B.; Plum, F., Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 1982, 11 (5), 491-8. (Pubitemid 12158810)
43. Pulsinelli, W. A.; Levy, D. E.; Duffy, T. E., Regional cerebral blood flow and glucose metabolism following transient forebrain ischemia. Ann Neurol 1982, 11 (5), 499-502.
44. Gluck, M. R.; Jayatilleke, E.; Shaw, S.; Rowan, A. J.; Haroutunian, V., CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res 2000, 39 (1), 63-71. (Pubitemid 30053124)
45. Chuang, D. M., Lithium protection from glutamate excitotoxicity: therapeutic implications. Clinical Neuroscience Research 2004, 4 (3-4), 243-252.
46. McDonald, J. W.; Johnston, M. V.; Young, A. B., Differential ontogenic development of three receptors comprising the NMDA receptor/channel complex in the rat hippocampus. Exp Neurol 1990, 110 (3), 237-47.
47. Tremblay, E.; Roisin, M. P.; Represa, A.; Charriaut-Marlangue, C.; Ben-Ari, Y., Transient increased density of NMDA binding sites in the developing rat hippocampus. Brain Res 1988, 461 (2), 393-6.
48. Johnston, M. V., Neurotransmitters and vulnerability of the developing brain. Brain Dev 1995, 17 (5), 301-6.
49. Sheng, M.; Cummings, J.; Roldan, L. A.; Jan, Y. N.; Jan, L. Y., Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 1994, 368 (6467), 144-7. (Pubitemid 24101524)
50. Parihar, M. S.; Brewer, G. J., Simultaneous age-related depolarization of mitochondrial membrane potential and increased mitochondrial reactive oxygen species production correlate with age-related glutamate excitotoxicity in rat hippocampal neurons. J Neurosci Res 2007, 85 (5), 1018-32. (Pubitemid 46580343)
51. Dong, X. X.; Wang, Y.; Qin, Z. H., Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009, 30 (4), 379-87.
52. Freeman, G. B.; Gibson, G. E., Selective alteration of mouse brain neurotransmitter release with age. Neurobiol Aging 1987, 8 (2), 147-52. (Pubitemid 17057193)
53. Baudry, M.; Arst, D. S.; Lynch, G., Increased [3H]glutamate receptor binding in aged rats. Brain Res 1981, 223 (1), 195-8. (Pubitemid 11022456)
54. Riedel, G.; Platt, B.; Micheau, J., Glutamate receptor function in learning and memory. Behav Brain Res 2003, 140 (1-2), 1-47. (Pubitemid 36313239)
55. Izquierdo, I., Pharmacological evidence for a role of long-term potentiation in memory. FASEB J 1994, 8 (14), 1139-45. (Pubitemid 24361519)
56. Rowland, L. M.; Astur, R. S.; Jung, R. E.; Bustillo, J. R.; Lauriello, J.; Yeo, R. A., Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005, 30 (3), 633-9. (Pubitemid 40271165)
57. Hardingham, G. E.; Bading, H., Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11 (10), 682-96.
58. Quartermain, D.; Mower, J.; Rafferty, M. F.; Herting, R. L.; Lanthorn, T. H., Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994, 257 (1-2), 7-12. (Pubitemid 24178543)
59. Mereu, G.; Fa, M.; Ferraro, L.; Cagiano, R.; Antonelli, T.; Tattoli, M.; Ghiglieri, V.; Tanganelli, S.; Gessa, G. L.; Cuomo, V., Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci U S A 2003, 100 (8), 4915-20. (Pubitemid 36457828)
60. Sakimura, K.; Kutsuwada, T.; Ito, I.; Manabe, T.; Takayama, C.; Kushiya, E.; Yagi, T.; Aizawa, S.; Inoue, Y.; Sugiyama, H.; et al., Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature 1995, 373 (6510), 151-5.
61. Tang, Y. P.; Shimizu, E.; Dube, G. R.; Rampon, C.; Kerchner, G. A.; Zhuo, M.; Liu, G.; Tsien, J. Z., Genetic enhancement of learning and memory in mice. Nature 1999, 401 (6748), 63-9.
62. Izquierdo, I.; Medina, J. H., Role of the amygdala, hippocampus and entorhinal cortex in memory consolidation and expression. Braz J Med Biol Res 1993, 26 (6), 573-89. (Pubitemid 23211446)
63. Morris, R. G.; Anderson, E.; Lynch, G. S.; Baudry, M., Selective impairment of learning and blockade of long-term potentiation by an N-methyl-Daspartate receptor antagonist, AP5. Nature 1986, 319 (6056), 774-6. (Pubitemid 16145031)
64. Sanders, M. J.; Fanselow, M. S., Pre-training prevents context fear conditioning deficits produced by hippocampal NMDA receptor blockade. Neurobiol Learn Mem 2003, 80 (2), 123-9. (Pubitemid 36970233)
65. Dalmau, J.; Gleichman, A. J.; Hughes, E. G.; Rossi, J. E.; Peng, X.; Lai, M.; Dessain, S. K.; Rosenfeld, M. R.; Balice-Gordon, R.; Lynch, D. R., Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7 (12), 1091-8.
66. Wandinger, K. P.; Saschenbrecker, S.; Stoecker, W.; Dalmau, J., Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011, 231 (1-2), 86-91.
67. Tamminga, C. A., Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998, 12 (1-2), 21-36. (Pubitemid 28177262)
68. Honey, G. D.; Honey, R. A.; O'Loughlin, C.; Sharar, S. R.; Kumaran, D.; Suckling, J.; Menon, D. K.; Sleator, C.; Bullmore, E. T.; Fletcher, P. C., Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 2005, 15 (6), 749-59. (Pubitemid 40703969)
69. Gecz, J., Glutamate receptors and learning and memory. Nat Genet 2010, 42 (11), 925-6.
70. Malenka, R. C., Synaptic plasticity and AMPA receptor trafficking. Ann N Y Acad Sci 2003, 1003, 1-11. (Pubitemid 38083041)
71. Keifer, J.; Zheng, Z., AMPA receptor trafficking and learning. Eur J Neurosci 2010, 32 (2), 269-77.
72. Martin, J. R.; Cumin, R.; Aschwanden, W.; Moreau, J. L.; Jenck, F.; Haefely, W. E., Aniracetam improves radial maze performance in rats. Neuroreport 1992, 3 (1), 81-3.
73. Cumin, R.; Bandle, E. F.; Gamzu, E.; Haefely, W. E., Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl) 1982, 78 (2), 104-11. (Pubitemid 13234084)
74. Ohno, M.; Yamamoto, T.; Kitajima, I.; Ueki, S., WEB 1881 FU ameliorates impairment of working memory induced by scopolamine and cerebral ischemia in the three-panel runway task. Jpn J Pharmacol 1990, 54 (1), 53-60. (Pubitemid 20259975)
75. Granger, R.; Staubli, U.; Davis, M.; Perez, Y.; Nilsson, L.; Rogers, G. A.; Lynch, G., A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse 1993, 15 (4), 326-9.
76. Staubli, U.; Ambros-Ingerson, J.; Lynch, G., Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors. Hippocampus 1992, 2 (1), 49-57.
77. Arai, A.; Kessler, M.; Xiao, P.; Ambros-Ingerson, J.; Rogers, G.; Lynch, G., A centrally active drug that modulates AMPA receptor gated currents. Brain Res 1994, 638 (1-2), 343-6. (Pubitemid 24063324)
78. Hampson, R. E.; Rogers, G.; Lynch, G.; Deadwyler, S. A., Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 1998, 18 (7), 2740-7.
79. Lynch, G.; Kessler, M.; Rogers, G.; Ambros-Ingerson, J.; Granger, R.; Schehr, R. S., Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol 1996, 11 (1), 13-9. (Pubitemid 26135298)
80. Lynch, G.; Granger, R.; Ambros-Ingerson, J.; Davis, C. M.; Kessler, M.; Schehr, R., Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 1997, 145 (1), 89-92. (Pubitemid 27244283)
81. Goff, D. C.; Lamberti, J. S.; Leon, A. C.; Green, M. F.; Miller, A. L.; Patel, J.; Manschreck, T.; Freudenreich, O.; Johnson, S. A., A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33 (3), 465-72.
82. Porrino, L. J.; Daunais, J. B.; Rogers, G. A.; Hampson, R. E.; Deadwyler, S. A., Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 2005, 3 (9), e299.
83. Wesensten, N. J.; Reichardt, R. M.; Balkin, T. J., Ampakine (CX717) effects on performance and alertness during simulated night shift work. Aviat Space Environ Med 2007, 78 (10), 937-43. (Pubitemid 47511951)
84. Feyder, M.; Wiedholz, L.; Sprengel, R.; Holmes, A., Impaired associative fear learning in mice with complete loss or haploinsufficiency of AMPA GluR1 receptors. Front Behav Neurosci 2007, 1, 4.
85. Clem, R. L.; Huganir, R. L., Calcium-permeable AMPA receptor dynamics mediate fear memory erasure. Science 2010, 330 (6007), 1108-12.
86. Fisahn, A., Kainate receptors and rhythmic activity in neuronal networks: hippocampal gamma oscillations as a tool. J Physiol 2005, 562 (Pt 1), 65-72. (Pubitemid 40207785)
87. Chamberlain, S. E.; Jane, D. E.; Jones, R. S., Pre- and post-synaptic functions of kainate receptors at glutamate and GABA synapses in the rat entorhinal cortex. Hippocampus 2011.
88. Ben-Ari, Y., Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985, 14 (2), 375-403. (Pubitemid 15169910)
89. Headley, D. B.; Weinberger, N. M., Gamma-band activation predicts both associative memory and cortical plasticity. J Neurosci 2011, 31 (36), 12748-58.
90. Aiba, A.; Chen, C.; Herrup, K.; Rosenmund, C.; Stevens, C. F.; Tonegawa, S., Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell 1994, 79 (2), 365-75. (Pubitemid 24324925)
91. Nielsen, K. S.; Macphail, E. M.; Riedel, G., Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats. Eur J Pharmacol 1997, 326 (2-3), 105-8. (Pubitemid 27214537)
92. Balschun, D.; Wetzel, W., Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats. Pharmacol Biochem Behav 2002, 73 (2), 375-80. (Pubitemid 34773439)
93. Naie, K.; Manahan-Vaughan, D., Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb Cortex 2004, 14 (2), 189-98. (Pubitemid 38141534)
94. Lu, Y. M.; Jia, Z.; Janus, C.; Henderson, J. T.; Gerlai, R.; Wojtowicz, J. M.; Roder, J. C., Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 1997, 17 (13), 5196-205. (Pubitemid 27263833)
95. Lyon, L.; Burnet, P. W.; Kew, J. N.; Corti, C.; Rawlins, J. N.; Lane, T.; De Filippis, B.; Harrison, P. J.; Bannerman, D. M., Fractionation of Spatial Memory in GRM2/3 (mGlu2/mGlu3) Double Knockout Mice Reveals a Role for Group II Metabotropic Glutamate Receptors at the Interface Between Arousal and Cognition. Neuropsychopharmacology 2011.
96. Umemura, K.; Gemba, T.; Mizuno, A.; Nakashima, M., Inhibitory effect of MS-153 on elevated brain glutamate level induced by rat middle cerebral artery occlusion. Stroke 1996, 27 (9), 1624-8. (Pubitemid 26295915)
97. Phillis, J. W.; Ren, J.; O'Regan, M. H., Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex: studies with DL-threo-beta-benzyloxyaspartate. Brain Res 2000, 880 (1-2), 224.
98. Morimoto, T.; Globus, M. Y.; Busto, R.; Martinez, E.; Ginsberg, M. D., Simultaneous measurement of salicylate hydroxylation and glutamate release in the penumbral cortex following transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1996, 16 (1), 92-9. (Pubitemid 26007954)
99. Davalos, A.; Shuaib, A.; Wahlgren, N. G., Neurotransmitters and pathophysiology of stroke: evidence for the release of glutamate and other transmitters/mediators in animals and humans. J Stroke Cerebrovasc Dis 2000, 9 (6 Pt 2), 2-8.
100. Khalessi, A. A.; Natarajan, S. K.; Orion, D.; Binning, M. J.; Siddiqui, A.; Levy, E. I.; Hopkins, L. N., Acute stroke intervention. JACC Cardiovasc Interv 2011, 4 (3), 261-9.
101. Hao, J.; Mdzinarishvili, A.; Abbruscato, T. J.; Klein, J.; Geldenhuys, W. J.; Van der Schyf, C. J.; Bickel, U., Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. Brain Res 2008, 1196, 113-20.
102. Li, Y.; Xu, Z.; Ford, G. D.; Croslan, D. R.; Cairobe, T.; Li, Z.; Ford, B. D., Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia. Brain Res 2007, 1184, 277-83. (Pubitemid 350160568)
103. Williams, A. J.; Dave, J. R.; Phillips, J. B.; Lin, Y.; McCabe, R. T.; Tortella, F. C., Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: in vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. J Pharmacol Exp Ther 2000, 294 (1), 378-86. (Pubitemid 30434711)
104. Tsuchida, E.; Rice, M.; Bullock, R., The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma 1997, 14 (6), 409-17. (Pubitemid 27293216)
105. Wang, C. X.; Shuaib, A., NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord 2005, 4 (2), 143-51. (Pubitemid 40612988)
106. Hoyte, L.; Barber, P. A.; Buchan, A. M.; Hill, M. D., The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med 2004, 4 (2), 131-6. (Pubitemid 38425910)
107. Muir, K. W., Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006, 6 (1), 53-60. (Pubitemid 43103819)
108. Slusher, B. S.; Vornov, J. J.; Thomas, A. G.; Hurn, P. D.; Harukuni, I.; Bhardwaj, A.; Traystman, R. J.; Robinson, M. B.; Britton, P.; Lu, X. C.; Tortella, F. C.; Wozniak, K. M.; Yudkoff, M.; Potter, B. M.; Jackson, P. F., Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999, 5 (12), 1396-402.
109. Kohara, A.; Takahashi, M.; Yatsugi, S.; Tamura, S.; Shitaka, Y.; Hayashibe, S.; Kawabata, S.; Okada, M., Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res 2008, 1191, 168-79.
110. Beschorner, R.; Dietz, K.; Schauer, N.; Mittelbronn, M.; Schluesener, H. J.; Trautmann, K.; Meyermann, R.; Simon, P., Expression of EAAT1 reflects a possible neuroprotective function of reactive astrocytes and activated microglia following human traumatic brain injury. Histol Histopathol 2007, 22 (5), 515-26. (Pubitemid 46647265)
111. Ketheeswaranathan, P.; Turner, N. A.; Spary, E. J.; Batten, T. F.; McColl, B. W.; Saha, S., Changes in glutamate transporter expression in mouse forebrain areas following focal ischemia. Brain Res 2011.
112. Mori, T.; Tateishi, N.; Kagamiishi, Y.; Shimoda, T.; Satoh, S.; Ono, S.; Katsube, N.; Asano, T., Attenuation of a delayed increase in the extracellular glutamate level in the peri-infarct area following focal cerebral ischemia by a novel agent ONO-2506. Neurochem Int 2004, 45 (2-3), 381-7. (Pubitemid 38625628)
113. Lawrence, A. D.; Sahakian, B. J., The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res 1998, 23 (5), 787-94. (Pubitemid 28173586)
114. Reisberg, B.; Doody, R.; Stoffler, A.; Schmitt, F.; Ferris, S.; Mobius, H. J., Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348 (14), 1333-41. (Pubitemid 36384100)
115. Winblad, B.; Poritis, N., Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999, 14 (2), 135-46. (Pubitemid 29110331)
116. Tariot, P. N.; Farlow, M. R.; Grossberg, G. T.; Graham, S. M.; McDonald, S.; Gergel, I., Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291 (3), 317-24. (Pubitemid 38101604)
117. Braak, H.; Braak, E., Alzheimer's disease affects limbic nuclei of the thalamus. Acta Neuropathol 1991, 81 (3), 261-8.
118. Thompson, P. M.; Hayashi, K. M.; Dutton, R. A.; Chiang, M. C.; Leow, A. D.; Sowell, E. R.; De Zubicaray, G.; Becker, J. T.; Lopez, O. L.; Aizenstein, H. J.; Toga, A. W., Tracking Alzheimer's disease. Ann N Y Acad Sci 2007, 1097, 183-214. (Pubitemid 47084892)
119. Miguel-Hidalgo, J. J.; Alvarez, X. A.; Cacabelos, R.; Quack, G., Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002, 958 (1), 210-21. (Pubitemid 35441230)
120. Parameshwaran, K.; Dhanasekaran, M.; Suppiramaniam, V., Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 2008, 210 (1), 7-13. (Pubitemid 351258072)
121. Mohamed, N. E.; Zhao, Y.; Lee, J. H.; Tan, M. G.; Esiri, M. M.; Wilcock, G. K.; Smith, A. D.; Wong, P. T.; Chen, C. P.; Lai, M. K., Upregulation of AMPA receptor GluR2 (GluA2) subunits in subcortical ischemic vascular dementia is repressed in the presence of Alzheimer's disease. Neurochem Int 2011.
122. Isaac, J. T.; Ashby, M. C.; McBain, C. J., The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron 2007, 54 (6), 859-71. (Pubitemid 46907505)
123. Richards, G.; Messer, J.; Faull, R. L.; Stadler, H.; Wichmann, J.; Huguenin, P.; Bohrmann, B.; Mutel, V., Altered distribution of mGlu2 receptors in beta-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice. Brain Res 2010, 1363, 180-90.
124. Roe, C. M.; Xiong, C.; Miller, J. P.; Morris, J. C., Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 2007, 68 (3), 223-8. (Pubitemid 46105742)
125. Olney, J. W.; Labruyere, J.; Wang, G.; Wozniak, D. F.; Price, M. T.; Sesma, M. A., NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254 (5037), 1515-8. (Pubitemid 21917493)
126. Corti, C.; Xuereb, J. H.; Crepaldi, L.; Corsi, M.; Michielin, F.; Ferraguti, F., Altered levels of glutamatergic receptors and Na+/K+ ATPase-alpha1 in the prefrontal cortex of subjects with schizophrenia. Schizophr Res 2011, 128 (1-3), 7-14.
127. Javitt, D. C.; Zukin, S. R., Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148 (10), 1301-8.
128. Krystal, J. H.; Karper, L. P.; Seibyl, J. P.; Freeman, G. K.; Delaney, R.; Bremner, J. D.; Heninger, G. R.; Bowers, M. B., Jr.; Charney, D. S., Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51 (3), 199-214. (Pubitemid 24081509)
129. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D., Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13 (9), 1102-7. (Pubitemid 47517511)
130. Hoff, A. L.; Sakuma, M.; Wieneke, M.; Horon, R.; Kushner, M.; DeLisi, L. E., Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 1999, 156 (9), 1336-41. (Pubitemid 29416528)
131. Cornblatt, B.; Obuchowski, M.; Roberts, S.; Pollack, S.; Erlenmeyer-Kimling, L., Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999, 11 (3), 487-508.
132. Nuechterlein, K. H.; Dawson, M. E.; Gitlin, M.; Ventura, J.; Goldstein, M. J.; Snyder, K. S.; Yee, C. M.; Mintz, J., Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress. Schizophr Bull 1992, 18 (3), 387-425.
133. Freedman, R.; Olincy, A.; Buchanan, R. W.; Harris, J. G.; Gold, J. M.; Johnson, L.; Allensworth, D.; Guzman-Bonilla, A.; Clement, B.; Ball, M. P.; Kutnick, J.; Pender, V.; Martin, L. F.; Stevens, K. E.; Wagner, B. D.; Zerbe, G. O.; Soti, F.; Kem, W. R., Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008, 165 (8), 1040-7.
134. Gottlieb, J. D.; Cather, C.; Shanahan, M.; Creedon, T.; Macklin, E. A.; Goff, D. C., d-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res 2011, 131 (1-3), 69-74.
135. Ramsey, A. J.; Milenkovic, M.; Oliveira, A. F.; Escobedo-Lozoya, Y.; Seshadri, S.; Salahpour, A.; Sawa, A.; Yasuda, R.; Caron, M. G., Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proc Natl Acad Sci U S A 2011, 108 (14), 5795-800.
136. Wallstrom, E.; Diener, P.; Ljungdahl, A.; Khademi, M.; Nilsson, C. G.; Olsson, T., Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 1996, 137 (2), 89-96. (Pubitemid 26172037)
137. Pitt, D.; Werner, P.; Raine, C. S., Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000, 6 (1), 67-70. (Pubitemid 30048528)
138. Smith, T.; Groom, A.; Zhu, B.; Turski, L., Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000, 6 (1), 62-6.
139. Stover, J. F.; Pleines, U. E.; Morganti-Kossmann, M. C.; Kossmann, T.; Lowitzsch, K.; Kempski, O. S., Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997, 27 (12), 1038-43. (Pubitemid 28012626)
140. Sarchielli, P.; Greco, L.; Floridi, A.; Gallai, V., Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 2003, 60 (8), 1082-8. (Pubitemid 36975795)
141. Matute, C.; Alberdi, E.; Domercq, M.; Perez-Cerda, F.; Perez-Samartin, A.; Sanchez-Gomez, M. V., The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001, 24 (4), 224-30. (Pubitemid 32204379)
142. Sarchielli, P.; Di Filippo, M.; Candeliere, A.; Chiasserini, D.; Mattioni, A.; Tenaglia, S.; Bonucci, M.; Calabresi, P., Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol 2007, 188 (1-2), 146-58. (Pubitemid 47095024)
143. Schulz, D.; Kopp, B.; Kunkel, A.; Faiss, J. H., Cognition in the early stage of multiple sclerosis. J Neurol 2006, 253 (8), 1002-10. (Pubitemid 44441123)
144. Rao, S. M., Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995, 8 (3), 216-20.
145. Arnett, P. A.; Strober, L. B., Cognitive and neurobehavioral features in multiple sclerosis. Expert Rev Neurother 2011, 11 (3), 411-24.
146. Glanz, B. I.; Holland, C. M.; Gauthier, S. A.; Amunwa, E. L.; Liptak, Z.; Houtchens, M. K.; Sperling, R. A.; Khoury, S. J.; Guttmann, C. R.; Weiner, H. L., Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler 2007, 13 (8), 1004-10. (Pubitemid 351541435)
147. Deloire, M. S.; Salort, E.; Bonnet, M.; Arimone, Y.; Boudineau, M.; Amieva, H.; Barroso, B.; Ouallet, J. C.; Pachai, C.; Galliaud, E.; Petry, K. G.; Dousset, V.; Fabrigoule, C.; Brochet, B., Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76 (4), 519-26. (Pubitemid 40486577)
148. Roosendaal, S. D.; Moraal, B.; Pouwels, P. J.; Vrenken, H.; Castelijns, J. A.; Barkhof, F.; Geurts, J. J., Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler 2009, 15 (6), 708-14.
149. Matute, C., Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci U S A 1998, 95 (17), 10229-34. (Pubitemid 28415323)
150. Villoslada, P.; Arrondo, G.; Sepulcre, J.; Alegre, M.; Artieda, J., Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009, 72 (19), 1630-3.
151. Rojas, C.; Frazier, S. T.; Flanary, J.; Slusher, B. S., Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem 2002, 310 (1), 50-4. (Pubitemid 35387330)
152. Yamamoto, T.; Nozaki-Taguchi, N.; Sakashita, Y.; Inagaki, T., Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 2001, 102 (2), 473-9. (Pubitemid 32126501)
153. Yamamoto, T.; Nozaki-Taguchi, N.; Sakashita, Y., Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res. 2001, 909 (1-2), 138-44. (Pubitemid 32710127)
154. Jackson, P. F.; Tays, K. L.; Maclin, K. M.; Ko, Y. S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X. C.; Wozniak, K.; Slusher, B. S., Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J. Med. Chem. 2001, 44 (24), 4170-5. (Pubitemid 33095323)
155. Chen, S. R.; Wozniak, K. M.; Slusher, B. S.; Pan, H. L., Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. 2002, 300 (2), 662-667.
156. Zhang, W.; Slusher, B.; Murakawa, Y.; Wozniak, K. M.; Tsukamoto, T.; Jackson, P. F.; Sima, A. A., GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 2002, 194 (1), 21-8. (Pubitemid 34051551)
157. Majer, P.; Jackson, P. F.; Delahanty, G.; Grella, B. S.; Ko, Y. S.; Li, W.; Liu, Q.; Maclin, K. M.; Polakova, J.; Shaffer, K. A.; Stoermer, D.; Vitharana, D.; Wang, E. Y.; Zakrzewski, A.; Rojas, C.; Slusher, B. S.; Wozniak, K. M.; Burak, E.; Limsakun, T.; Tsukamoto, T., Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J. Med. Chem. 2003, 46 (10), 1989-96. (Pubitemid 36532241)
158. Carpenter, K. J.; Sen, S.; Matthews, E. A.; Flatters, S. L.; Wozniak, K. M.; Slusher, B. S.; Dickenson, A. H., Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. Neuropeptides 2003, 37 (5), 298-306. (Pubitemid 37464033)
159. Kozikowski, A. P.; Zhang, J.; Nan, F.; Petukhov, P. A.; Grajkowska, E.; Wroblewski, J. T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J. H., Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004, 47 (7), 1729-38. (Pubitemid 38380916)
160. Yamamoto, T.; Hirasawa, S.; Wroblewska, B.; Grajkowska, E.; Zhou, J.; Kozikowski, A.; Wroblewski, J.; Neale, J. H., Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 2004, 20 (2), 483-94. (Pubitemid 38969633)
161. Zhang, W.; Murakawa, Y.; Wozniak, K. M.; Slusher, B.; Sima, A. A., The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 2006, 247 (2), 217-23. (Pubitemid 44301265)
162. Nagel, J.; Belozertseva, I.; Greco, S.; Kashkin, V.; Malyshkin, A.; Jirgensons, A.; Shekunova, E.; Eilbacher, B.; Bespalov, A.; Danysz, W., Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology 2006, 51, 1163-71. (Pubitemid 44715967)
163. Yamamoto, T.; Saito, O.; Aoe, T.; Bartolozzi, A.; Sarva, J.; Zhou, J.; Kozikowski, A.; Wroblewska, B.; Bzdega, T.; Neale, J. H., Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci 2007, 25 (1), 147-58. (Pubitemid 46098894)
164. Saito, O.; Aoe, T.; Kozikowski, A.; Sarva, J.; Neale, J. H.; Yamamoto, T., Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. Can J Anaesth 2006, 53 (9), 891-8. (Pubitemid 44696513)
165. Yamamoto, T.; Kozikowski, A.; Zhou, J.; Neale, J. H., Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Mol Pain 2008, 4, 31.
166. Adedoyin, M. O.; Vicini, S.; Neale, J. H., Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Mol Pain 6, 60.
167. Slusher, B. S.; Vornov, J. J.; Thomas, A. G.; Hurn, P. D.; Harukuni, I.; Bhardwaj, A.; Traystman, R. J.; Robinson, M. B.; Britton, P.; Lu, X. C.; Tortella, F. C.; Wozniak, K. M.; Yudkoff, M.; Potter, B. M.; Jackson, P. F., Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 1999, 5 (12), 1396-402.
168. Tortella, F. C.; Lin, Y.; Ved, H.; Slusher, B. S.; Dave, J. R., Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. Eur J Pharmacol 2000, 402 (1-2), 31-7. (Pubitemid 30625307)
169. Harada, C.; Harada, T.; Slusher, B. S.; Yoshida, K.; Matsuda, H.; Wada, K., N-acetylated-alpha-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia. Neurosci Lett 2000, 292 (2), 134-6.
170. Williams, A. J.; Lu, X. M.; Slusher, B.; Tortella, F. C., Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats. J. Pharmacol. Exp. Ther. 2001, 299 (1), 48-57. (Pubitemid 32905117)
171. Jackson, P. F.; Tays, K. L.; Maclin, K. M.; Ko, Y. S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X. C.; Wozniak, K.; Slusher, B. S., Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem 2001, 44 (24), 4170-5. (Pubitemid 33095323)
172. Ghadge, G. D.; Slusher, B. S.; Bodner, A.; Canto, M. D.; Wozniak, K.; Thomas, A. G.; Rojas, C.; Tsukamoto, T.; Majer, P.; Miller, R. J.; Monti, A. L.; Roos, R. P., Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A 2003, 100 (16), 9554-9. (Pubitemid 37033966)
173. Long, J. B.; Yourick, D. L.; Slusher, B. S.; Robinson, M. B.; Meyerhoff, J. L., Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. Eur J Pharmacol 2005, 508 (1-3), 115-22. (Pubitemid 40169909)
174. Zhong, C.; Zhao, X.; Sarva, J.; Kozikowski, A.; Neale, J. H.; Lyeth, B. G., NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotrauma 2005, 22 (2), 266-76. (Pubitemid 40333520)
175. Zhong, C.; Zhao, X.; Van, K. C.; Bzdega, T.; Smyth, A.; Zhou, J.; Kozikowski, A. P.; Jiang, J.; O'Connor W, T.; Berman, R. F.; Neale, J. H.; Lyeth, B. G., NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem 2006, 97 (4), 1015-25.
176. Berent-Spillson, A.; Robinson, A. M.; Golovoy, D.; Slusher, B.; Rojas, C.; Russell, J. W., Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. J Neurochem 2004, 89 (1), 90-9. (Pubitemid 38420677)
177. Carozzi, V. A.; Chiorazzi, A.; Canta, A.; Lapidus, R. G.; Slusher, B. S.; Wozniak, K. M.; Cavaletti, G., Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 17 (4), 380-91.
178. Witkin, J. M.; Gasior, M.; Schad, C.; Zapata, A.; Shippenberg, T.; Hartman, T.; Slusher, B. S., NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 2002, 43 (3), 348-56. (Pubitemid 35257926)
179. McKinzie, D. L.; Li, T.-K.; McBride, W. J.; Slusher, B. S., NAALADase inhibition reduces alcohol consumption in the alcohol-preferring (P) line of rats. Addiction Biology 2000, 5, 411-416.
180. Shippenberg, T. S.; Rea, W.; Slusher, B. S., Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse 2000, 38 (2), 161-6.
181. Slusher, B. S.; Thomas, A.; Paul, M.; Schad, C. A.; Ashby, C. R., Jr., Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-alpha-linked-acidic dipeptidase (NAALADASE). Synapse 2001, 41 (1), 22-8.
182. Kozela, E.; Wrobel, M.; Kos, T.; Wojcikowski, J.; Daniel, W. A.; Wozniak, K. M.; Slusher, B. S.; Popik, P., 2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice. Psychopharmacology (Berl) 2005, 183 (3), 275-84. (Pubitemid 41660412)
183. Xi, Z. X.; Kiyatkin, M.; Li, X.; Peng, X. Q.; Wiggins, A.; Spiller, K.; Li, J.; Gardner, E. L., N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology 58 (1), 304-13.
184. Xi, Z. X.; Li, X.; Peng, X. Q.; Li, J.; Chun, L.; Gardner, E. L.; Thomas, A. G.; Slusher, B. S.; Ashby, C. R., Jr., Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 112 (2), 564-76.
185. Peng, X. Q.; Li, J.; Gardner, E. L.; Ashby, C. R., Jr.; Thomas, A.; Wozniak, K.; Slusher, B. S.; Xi, Z. X., Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol 627 (1-3), 156-61.
186. Wroblewska, B.; Santi, M. R.; Neale, J. H., N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 1998, 24 (2), 172-9. (Pubitemid 28403995)
187. Wroblewska, B.; Wroblewski, J. T.; Pshenichkin, S.; Surin, A.; Sullivan, S. E.; Neale, J. H., N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 1997, 69 (1), 174-81. (Pubitemid 27274170)
188. Caraci, F.; Molinaro, G.; Battaglia, G.; Giuffrida, M. L.; Riozzi, B.; Traficante, A.; Bruno, V.; Cannella, M.; Merlo, S.; Wang, X.; Heinz, B. A.; Nisenbaum, E. S.; Britton, T. C.; Drago, F.; Sortino, M. A.; Copani, A.; Nicoletti, F., Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol 2011, 79 (3), 618-26.
189. Wozniak, D. F.; Brosnan-Watters, G.; Nardi, A.; McEwen, M.; Corso, T. D.; Olney, J. W.; Fix, A. S., MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res 1996, 707 (2), 165-79. (Pubitemid 26057583)
190. Brosnan-Watters, G.; Wozniak, D. F.; Nardi, A.; Olney, J. W., Acute behavioral effects of MK-801 in the mouse. Pharmacol Biochem Behav 1996, 53 (3), 701-11. (Pubitemid 26086455)
191. Wozniak, D. F.; Olney, J. W.; Kettinger, L., 3rd; Price, M.; Miller, J. P., Behavioral effects of MK-801 in the rat. Psychopharmacology (Berl) 1990, 101 (1), 47-56. (Pubitemid 20124741)
192. Lukawski, K.; Kaminski, R. M.; Czuczwar, S. J., Effects of selective inhibition of N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) on mice in learning and memory tasks. Eur J Pharmacol 2008, 579 (1-3), 202-7.
193. Ziehn, M. O.; Avedisian, A. A.; Tiwari-Woodruff, S.; Voskuhl, R. R., Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 2010, 90 (5), 774-86.
194. Bacich, D. J.; Wozniak, K. M.; Lu, X. C.; O'Keefe, D. S.; Callizot, N.; Heston, W. D.; Slusher, B. S., Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J Neurochem 2005, 95 (2), 314-23. (Pubitemid 41457500)